Hair Depigmentation and Vitiligo-like Lesions in a Leukaemic Paediatric Patient during Chemotherapy with Dasatinib

被引：17

作者：

Brazzelli, Valeria ^{[1
]}

Grasso, Vincenzo ^{[1
]}

Barbaccia, Vincenzo ^{[1
]}

Manna, Giambattista ^{[1
]}

Rivetti, Nicolo ^{[1
]}

Zecca, Marco ^{[2
,3
]}

Giorgiani, Giovanna ^{[2
,3
]}

Vassallo, Camilla ^{[1
]}

Borroni, Giovanni ^{[1
]}

机构：

[1] Univ Pavia, Inst Dermatol, Dept Human & Hereditary Pathol, IT-27100 Pavia, Italy

[2] Univ Pavia, Dept Haematol Oncol, Inst Paediat Sci, IT-27100 Pavia, Italy

[3] Fdn IRCCS Policlin San Matteo, IT-27100 Pavia, Italy

来源：

ACTA DERMATO-VENEREOLOGICA | 2012年 / 92卷 / 02期

关键词：

TYROSINE KINASE INHIBITOR; HOMEOSTASIS;

D O I：

10.2340/00015555-1289

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100227 [皮肤病学];

摘要：

引用

页码：218 / 219

页数：2

共 13 条

[1]

Aguilera Dolly G, 2009, Ther Clin Risk Manag, V5, P281

[2]

Recurrent neutrophilic panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib mesilate and dasatinib [J].

de Masson, A. ;

Bouvresse, S. ;

Clerici, T. ;

Mahe, E. ;

Saiag, P. .

ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2011, 138 (02) :135-139

[3]

The SCF/KIT pathway plays a critical role in the control of normal human melanocyte homeostasis [J].

Grichnik, JM ;

Burch, JA ;

Burchette, J ;

Shea, CR .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1998, 111 (02) :233-238

[4]

Tyrosine Kinase Inhibitors - A Review on Pharmacology, Metabolism and Side Effects [J].

Hartmann, Joerg Thomas ;

Haap, Michael ;

Kopp, Hans-Georg ;

Lipp, Hans-Peter .

CURRENT DRUG METABOLISM, 2009, 10 (05) :470-481

[5]

Practical Advice for Determining the Role of BCR-ABL Mutations in Guiding Tyrosine Kinase Inhibitor Therapy in Patients With Chronic Myeloid Leukemia [J].

Jabbour, Elias ;

Branford, Susan ;

Saglio, Giuseppe ;

Jones, Dan ;

Cortes, Jorge E. ;

Kantarjian, Hagop M. .

CANCER, 2011, 117 (09) :1800-1811

[6]

KURZROCK R, 1988, NEW ENGL J MED, V319, P990

[7]

Lindauer M, 2010, RECENT RESULTS CANC, V184, P83, DOI 10.1007/978-3-642-01222-8_7

[8]

Dasatinib, a Multikinase Inhibitor: Therapy, Safety, and Appropriate Management of Adverse Events [J].

Shayani, Sepideh .

THERAPEUTIC DRUG MONITORING, 2010, 32 (06) :680-687

[9]

Dasatinib: A tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia [J].

Steinberg, Michael .

CLINICAL THERAPEUTICS, 2007, 29 (11) :2289-2308

[10]

Sun A, 2009, J DRUGS DERMATOL, V8, P395

← 1 2 →